Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017.

IF 1.8 Q3 ONCOLOGY Radiation Oncology Journal Pub Date : 2023-06-01 DOI:10.3857/roj.2023.00353
Bong Kyung Bae, Jeong Il Yu, Hee Chul Park, Myung Ji Goh, Yong-Han Paik
{"title":"Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017.","authors":"Bong Kyung Bae,&nbsp;Jeong Il Yu,&nbsp;Hee Chul Park,&nbsp;Myung Ji Goh,&nbsp;Yong-Han Paik","doi":"10.3857/roj.2023.00353","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To report the trends of radiotherapy in the management of elderly patients with hepatocellular carcinoma (HCC).</p><p><strong>Materials and methods: </strong>We retrospectively reviewed patients who entered HCC registry of Samsung Medical Center between 2005 and 2017. Patients who were 75 years or older at the time of registration were defined as elderly. They were categorized into three groups based on the year of registration. Radiotherapy characteristics were compared between the groups to observe differences by age groups and period of registration.</p><p><strong>Results: </strong>Out of 9,132 HCC registry patients, elderly comprised 6.2% (566 patients) of the registry, and the proportion increased throughout the study period (from 3.1% to 11.4%). Radiotherapy was administered to 107 patients (18.9%) in elderly group. Radiotherapy utilization in the early treatment process (within 1 year after registration) has rapidly increased from 6.1% to 15.3%. All treatments before 2008 were delivered with two-dimensional or three-dimensional conformal radiotherapy, while more than two-thirds of treatments after 2017 were delivered with advanced techniques such as intensity-modulated radiotherapy, stereotactic body radiotherapy, or proton beam therapy. Overall survival (OS) of elderly was significantly worse than younger patients. However, for patients who received radiotherapy during the initial management (within one month after registration), there was no statistically significant difference in OS between age groups.</p><p><strong>Conclusion: </strong>The proportion of elderly HCC is increasing. Radiotherapy utilization and adoption of advanced radiotherapy technique showed a consistently increasing trend for the group of patients, indicating that the role of radiotherapy in the management of elderly HCC is expanding.</p>","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ec/68/roj-2023-00353.PMC10326507.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3857/roj.2023.00353","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Purpose: To report the trends of radiotherapy in the management of elderly patients with hepatocellular carcinoma (HCC).

Materials and methods: We retrospectively reviewed patients who entered HCC registry of Samsung Medical Center between 2005 and 2017. Patients who were 75 years or older at the time of registration were defined as elderly. They were categorized into three groups based on the year of registration. Radiotherapy characteristics were compared between the groups to observe differences by age groups and period of registration.

Results: Out of 9,132 HCC registry patients, elderly comprised 6.2% (566 patients) of the registry, and the proportion increased throughout the study period (from 3.1% to 11.4%). Radiotherapy was administered to 107 patients (18.9%) in elderly group. Radiotherapy utilization in the early treatment process (within 1 year after registration) has rapidly increased from 6.1% to 15.3%. All treatments before 2008 were delivered with two-dimensional or three-dimensional conformal radiotherapy, while more than two-thirds of treatments after 2017 were delivered with advanced techniques such as intensity-modulated radiotherapy, stereotactic body radiotherapy, or proton beam therapy. Overall survival (OS) of elderly was significantly worse than younger patients. However, for patients who received radiotherapy during the initial management (within one month after registration), there was no statistically significant difference in OS between age groups.

Conclusion: The proportion of elderly HCC is increasing. Radiotherapy utilization and adoption of advanced radiotherapy technique showed a consistently increasing trend for the group of patients, indicating that the role of radiotherapy in the management of elderly HCC is expanding.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
老年肝细胞癌放疗趋势:2005 - 2017年诊断患者的回顾性分析
目的:报道放射治疗在老年肝细胞癌(HCC)治疗中的发展趋势。材料和方法:我们回顾性分析了2005年至2017年在三星首尔医院登记的HCC患者。登记时年龄在75岁或以上的患者被定义为老年人。他们根据注册年份分为三组。比较各组放射治疗特点,观察各年龄组和登记时间的差异。结果:在9132例HCC登记患者中,老年人占登记患者的6.2%(566例),并且该比例在整个研究期间增加(从3.1%增加到11.4%)。老年组放疗107例(18.9%)。早期治疗过程(登记后1年内)的放疗利用率从6.1%迅速上升到15.3%。2008年之前的所有治疗均采用二维或三维适形放疗,而2017年之后超过三分之二的治疗采用调强放疗、立体定向体放疗或质子束治疗等先进技术。老年患者的总生存期(OS)明显低于年轻患者。然而,对于在初始治疗期间(登记后1个月内)接受放疗的患者,年龄组之间的OS无统计学差异。结论:老年HCC发病率呈上升趋势。放疗的使用和先进放疗技术的采用在该组患者中呈持续增加的趋势,表明放疗在老年HCC治疗中的作用正在扩大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.50
自引率
4.30%
发文量
24
期刊最新文献
Implementing high-dose rate surface mould brachytherapy for carcinoma of eyelid: a practical approach and weekly review The effects of high-dose radiation therapy on bone: a scoping review Validation of Combs prognostic scoring system in Indian recurrent glioma patients treated with re-radiation Long-term toxicities after allogeneic hematopoietic stem cell transplantation with or without total body irradiation: a population-based study in Korea Proton beam therapy as a promising option for high-risk limited stage small cell lung cancer: revealing potential of future novel agents
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1